Find information on thousands of medical conditions and prescription drugs.

Neuroleptic malignant syndrome

Neuroleptic malignant syndrome (NMS) is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. It is considered to be a very serious neurological disorder. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
Narcolepsy
Necrophobia
Necrotizing fasciitis
Neisseria meningitidis
Nemaline myopathy
Neonatal hemochromatosis
Neophobia
Nephophobia
Nephrogenic diabetes...
Nephrotic syndrome
Neuraminidase deficiency
Neurasthenia
Neuroacanthocytosis
Neuroblastoma
Neurofibrillary tangles
Neurofibroma
Neurofibromatosis
Neurofibromatosis type 2
Neuroleptic malignant...
Niemann-Pick Disease
Nijmegen Breakage Syndrome
Nocardiosis
Noma
Non-Hodgkin lymphoma
Noonan syndrome
Norrie disease
Nosophobia
Nyctophobia
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Causes

NMS is caused almost exclusively by antipsychotics, which includes all types of neuroleptic medicines along with newer antipsychotic drugs. The higher the dosage, the more common the occurrence. Rapid and large increases in dosage can also be attributed to the development of NMS. Other drugs, environmental or psychological factors, hereditary conditions, and specific demographics may be at greater risk, but to date no conclusive evidence has been found to support this. The disorder typically develops within two weeks of the initial treatment with the drug, but may develop at any time that the drug is being taken. NMS may also occur in people taking a class of drugs known as dopaminergics.

Symptoms

The first symptom to develop is usually muscular rigidity, followed by high fever and changes in cognitive functions. Other symptoms can vary, but may be unstable blood pressure, confusion, coma, delirium, muscle tremors, etc. Once symptoms do appear, they rapidly progress and can reach peak intensity in no more than three days. These symptoms can last as little as eight hours or as long as forty days.

Prognosis

As with most illnesses, the prognosis is best when identified early and treated aggressively. In these cases, NMS is usually not fatal, although there is currently no agreement on the exact mortality rate for the disorder. Studies have given the disorder a mortality rate as low as 5% and as high as 76%, although most studies agree that the correct percentage is in the lower spectrum, perhaps between 10% - 20%. Re-introduction to the drug that originally caused NMS to develop may also trigger a recurrence, although in most cases it does not.

Treatment

Although treatment is not always necessary, it will help to cure the disease and prevent fatal developments from occurring. The first step in treatment is generally to remove the patient from any neuroleptic or antipsychotic drugs being taken and to treat fever agressively. Many cases require intensive care, or some kind of supportive care at the minimum. Depending on the severity of the case, patients may require other treatments to contend with specific effects of the disorder. These include circulator and ventilatory support, the drugs dantrolene sodium, bromocriptine, apomorphine and electroconvulsive therapy (ECT) if medication fails.

Read more at Wikipedia.org


[List your site here Free!]


New Look at antipsychotic side effect - neuroleptic malignant syndrome
From Science News, 10/31/87

New look at antipsychotic side effect

Psychiatrists at McLean Hospital in Belmont, Mass., recently reviewed patient records at their facility and found that, over one year, about 1.4 percent of the patients given antipsychotic drugs developed a potentially fatal side effect known as neuroleptic malignant syndrome (NMS) (SN: 10/25/86, p.260). Initial signs of the reaction are fever, severe muscle rigidity and elevated heart rate and blood pressure. In some cases, coma, kidney failure, brain damage or even death can follow.

To check their "retrospective' estimate, the researchers tracked new cases of NMS over 18 months at the hospital. NMS was diagnosed in six of 679 antipsychotic-treated patients, report Paul E. Keck Jr. and his colleagues in the Oct. AMERICAN JOURNAL OF PSYCHIATRY.

Combined data from the prior review and the new survey point to an estimated NMS frequency of about 1 percent, they conclude. Nevertheless, diagnostic criteria for NMS, particularly in its early stages, remain nuclear to some investigators. The McLean psychiatrists say NMS may encompass a spectrum of physiological reactions to antipsychotic drugs, with mild and more severe forms.

COPYRIGHT 1987 Science Service, Inc.
COPYRIGHT 2004 Gale Group

Return to Neuroleptic malignant syndrome
Home Contact Resources Exchange Links ebay